Skip to main content

Home/ Pharmaceutical Laboratory/ Group items tagged aspirine

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
hamelinclara

1,2 million de sachets d'aspirine contrefaits saisis au Havre - 0 views

www.usinenouvelle.com/...efaits-saisis-au-havre.N197593

contrefaçon aspirine

shared by hamelinclara on 28 May 13 - No Cached
  • Le ministère de l’Economie a annoncé, samedi 26 mai, la saisie de plus d’un million de sachets d’aspirine contrefaits. Les médicaments étaient dissimulés dans un chargement de thé en provenance de Chine. "La plus importante saisie de contrefaçon de médicaments jamais réalisée par les services douaniers en France et dans l'Union Européenne". C'est en ces termes que le ministère de l’Economie a qualifié la découverte d'aspirines contrefaites au Havre le 17 mai dernier. Les sachets étaient dissimulés dans un chargement de thé en provenance de Chine. Ils "devaient être livrées au sein d'une société espagnole localisée aux îles Baléares présentant tous les aspects d'une société écran, et étaient sans doute destinées à être vendues dans la péninsule ibérique, le sud de la France et l'Afrique francophone", précise le ministère. La poudre contenue dans les médicaments ne renfermait aucun principe actif de l’aspirine. Elle était essentiellement composée de glucose. En 2012, 100 000 contrefaçons de médicaments ont été découvertes par les douaniers français, rappelle le communiqué.
hamelinclara

The search for blockbuster drugs - McKinsey Quarterly - Health Care - Pharmaceuticals - 1 views

www.mckinseyquarterly.com/rch_for_blockbuster_drugs_1474

blockbuster drugs Pharma

shared by hamelinclara on 09 Jan 13 - No Cached
  • "me-too" compounds,
  • heir efficacy, or comparative effectiveness in treating a specific disease
  • safety, including issues such as side effects and drug interactions
  • ...10 more annotations...
  • the breadth of their approved uses
  • convenience, including longer-lasting formulas and easier application
  • highly effective,
  • costly and inconclusive.
  • By contrast, many companies have had more success with efforts to improve the safety of products or to get them approved for use in treating additional diseases. Examples are Pfizer's Neurontin, a successful antiepilepsy medication driven predominantly by perceptions of safety differences, and the company's Celebrex, a Cox-2 inhibitor that reduces pain and inflammation and is thought to be easier on the stomach than aspirin. The breadth of approved uses for drugs can also be a significant source of differentiation. We found that nearly two-thirds of those in competitive therapeutic areas, such as depression and allergies, went on to receive regulatory approval for a broader range of treatments after they came on the market (Exhibit 2). Eli Lilly's Prozac, for example, was launched in 1987 to treat depression but has since been approved for use in a range of conditions. Today, drugs entering these competitive areas often need to have a similarly broad range of regulatory endorsements at the time of their launch, thereby raising the bar for compounds in development
  • pharmaceutical companies might rethink their strategies for clinical trials
  • oo many companies commit a disproportionate amount of their time and money to discovering first-in-class compounds when best-in-class opportunities might yield higher returns
  • Second, efficacy shouldn't be pursued at the expense of other sources of differentiation; claims of safety, pharmacokinetics (that is, dosing), and convenience may be as desirable and more clinically attainable
  • one meaningful point of differentiation and scuttle drugs that have even a single subpar attribute.

  • Of the recent blockbusters we analyzed, 59 percent were superior to the competition in only one area, while just 14 percent were superior in two, and no drug was the leader in three or more (Exhibit 3). While some of the remaining 27 percent were distinctive at launch, they are now comparable to their competitors in all significant dimensions but continue to be marketed more effectively. Yet drugs with even a single subpar attribute were generally commercial failures.1

    Back to top

    These

1 - 3 of 3
Showing 20▼ items per page